

**Green Cross Health Limited**  
**Consolidated interim financial statements**  
**Half year ended 30 September 2024**

## Contents

	Page
Half-year financial statements	
Consolidated interim statement of comprehensive income	2
Consolidated interim statement of changes in equity	3
Consolidated interim statement of financial position	4
Consolidated interim statement of cash flows	5
Notes to the consolidated financial statements	6
Company Directory	12

**Green Cross Health Limited**  
**Consolidated interim statement of comprehensive income**  
For the six months ended 30 September 2024

	Note	Six months ended 30 Sep 2024 (Unaudited) \$'000	Six months ended 30 Sep 2023 (Unaudited) \$'000
<b>Operating revenue</b>	3	<u>259,877</u>	<u>250,179</u>
<b>Operating expenditure</b>	4.2	<u>(234,979)</u>	<u>(226,270)</u>
Depreciation and amortisation expense		(2,442)	(2,704)
Depreciation - leases		(7,155)	(7,000)
Share of equity accounted net earnings		<u>802</u>	<u>728</u>
<b>Operating profit before interest and tax</b>		<b>16,103</b>	<b>14,933</b>
Interest income		290	357
Interest expense		(1,170)	(1,176)
Interest expense - leases		<u>(4,113)</u>	<u>(3,597)</u>
<b>Net interest expense</b>		<u>(4,993)</u>	<u>(4,416)</u>
<b>Profit before tax</b>		<b>11,110</b>	<b>10,517</b>
Income tax expense		<u>(3,021)</u>	<u>(2,848)</u>
<b>Profit for the period</b>		<b>8,089</b>	<b>7,669</b>
Other comprehensive income for the period, net of tax		<u>-</u>	<u>-</u>
<b>Total comprehensive income for the period</b>		<b><u>8,089</u></b>	<b><u>7,669</u></b>
<b>Attributable to:</b>			
Shareholders of the Parent		5,647	5,607
Non-controlling interest		<u>2,442</u>	<u>2,062</u>
		<b><u>8,089</u></b>	<b><u>7,669</u></b>
<b>Earnings per share:</b>			
Basic earnings per share (cents)		3.93	3.91
Diluted earnings per share (cents)		3.93	3.90

The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim financial statements.

**Green Cross Health Limited**  
**Consolidated interim statement of changes in equity**  
For the six months ended 30 September 2024

	Note	Share capital \$'000	Share based payment reserves \$'000	Retained earnings \$'000	Non- controlling interest \$'000	Total equity \$'000
Balance at 1 April 2023 (Audited)		90,760	583	100,065	10,597	202,005
Profit for the period		-	-	5,607	2,062	7,669
<b>Total comprehensive income for the period</b>		-	-	<b>5,607</b>	<b>2,062</b>	<b>7,669</b>
Distributions to non-controlling interests		-	-	-	(1,991)	(1,991)
Impacts of other transactions		-	-	129	71	200
Dividends to shareholders	7	-	-	(45,296)	-	(45,296)
Performance share rights charged to SOCI		-	50	-	-	50
Performance share rights vested		183	(183)	-	-	-
<b>Balance as at 30 September 2023 (Unaudited)</b>		<b>90,943</b>	<b>450</b>	<b>60,505</b>	<b>10,739</b>	<b>162,637</b>
Balance at 1 April 2024 (Audited)		90,943	450	62,875	12,340	166,608
Profit for the period		-	-	5,647	2,442	8,089
<b>Total comprehensive income for the period</b>		-	-	<b>5,647</b>	<b>2,442</b>	<b>8,089</b>
Distributions to non-controlling interests		-	-	-	(1,191)	(1,191)
Impacts of other transactions		-	-	(1,003)	(296)	(1,299)
Dividends to shareholders	7	-	-	(2,882)	-	(2,882)
Performance share rights vested		150	(150)	-	-	-
<b>Balance as at 30 September 2024 (Unaudited)</b>		<b>91,093</b>	<b>300</b>	<b>64,637</b>	<b>13,295</b>	<b>169,325</b>

The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim financial statements.

**Green Cross Health Limited**  
**Consolidated interim statement of financial position**  
**As at 30 September 2024**

	Note	As at 30 Sep 2024 (Unaudited) \$'000	As at 30 Sep 2023 (Unaudited) \$'000	As at 31 Mar 2024 (Audited) \$'000
<b>ASSETS</b>				
<b>Current assets</b>				
Cash and cash equivalents		28,852	18,450	23,402
Trade and other receivables		12,791	17,705	13,035
Contract assets		11,489	11,880	12,514
Inventories		33,075	32,777	30,445
Income taxes refundable		3,736	1,193	404
<b>Total current assets</b>		<b>89,943</b>	<b>82,005</b>	<b>79,800</b>
<b>Non-current assets</b>				
Other receivables		2,782	2,553	2,693
Property, plant and equipment		19,256	20,182	18,979
Right-of-use assets		94,876	91,582	97,084
Intangible assets		165,890	159,809	165,937
Deferred tax assets		12,258	11,984	11,977
Equity accounted group investments		7,298	6,823	6,816
<b>Total non-current assets</b>		<b>302,360</b>	<b>292,933</b>	<b>303,486</b>
<b>Total assets</b>		<b>392,303</b>	<b>374,938</b>	<b>383,286</b>
<b>LIABILITIES</b>				
<b>Current liabilities</b>				
Trade payables and accruals		69,449	70,320	63,074
Contract liabilities		10,601	8,173	9,021
Borrowings		1,822	1,878	2,573
Lease liabilities		12,371	12,796	13,098
<b>Total current liabilities</b>		<b>94,243</b>	<b>93,167</b>	<b>87,766</b>
<b>Non-current liabilities</b>				
Borrowings		32,703	29,501	32,372
Lease liabilities		96,032	89,633	96,540
<b>Total non-current liabilities</b>		<b>128,735</b>	<b>119,134</b>	<b>128,912</b>
<b>Total liabilities</b>		<b>222,978</b>	<b>212,301</b>	<b>216,678</b>
<b>Net assets</b>		<b>169,325</b>	<b>162,637</b>	<b>166,608</b>
<b>EQUITY</b>				
Share capital	6	91,093	90,943	90,943
Share based payment reserve		300	450	450
Retained earnings		64,637	60,505	62,875
Total equity attributable to shareholders of the Parent		156,030	151,898	154,268
Non-controlling interest		13,295	10,739	12,340
<b>Total equity</b>		<b>169,325</b>	<b>162,637</b>	<b>166,608</b>

The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim financial statements.

**Green Cross Health Limited**  
**Consolidated interim statement of cash flows**  
For the six months ended 30 September 2024

	Note	Six months ended 30 Sep 2024 (Unaudited) \$'000	Six months ended 30 Sep 2023 (Unaudited) \$'000
<b>Cash flows from operating activities</b>			
Dividends received		352	888
Receipts from customers		261,146	247,513
Interest received		256	225
Payments to suppliers and employees		(229,909)	(223,883)
Income taxes paid		(6,578)	(6,419)
<b>Net cash inflow from operating activities</b>	5	<b><u>25,267</u></b>	<b><u>18,324</u></b>
<b>Cash flows from investing activities</b>			
Purchases of property, plant and equipment and software intangibles		(2,192)	(3,184)
Acquisition of interests in equity accounted investments		-	(233)
Acquisition of interests in subsidiaries and non-controlling interests		(1,466)	(4,439)
<b>Net cash outflow from investing activities</b>		<b><u>(3,658)</u></b>	<b><u>(7,856)</u></b>
<b>Cash flows from financing activities</b>			
Proceeds from borrowings		540	11,100
Repayment of borrowings		(960)	(3,258)
Payment of lease liabilities		(6,082)	(6,181)
Interest expense		(1,222)	(1,184)
Interest expense - leases		(4,113)	(3,597)
Distributions to non-controlling interest		(1,568)	(2,245)
Dividend paid		(2,882)	(45,296)
<b>Net cash outflow from financing activities</b>		<b><u>(16,287)</u></b>	<b><u>(50,661)</u></b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>5,322</b>	<b>(40,193)</b>
Cash and cash equivalents at the beginning of the financial year		23,402	58,215
Cash acquired: business combinations		128	428
<b>Cash and cash equivalents at the end of the period</b>		<b><u>28,852</u></b>	<b><u>18,450</u></b>
<b>Reconciliation of closing cash and cash equivalents to the consolidated interim statement of financial position:</b>			
Cash and cash equivalents		<u>28,852</u>	<u>18,450</u>
<b>Closing cash and cash equivalents</b>		<b><u>28,852</u></b>	<b><u>18,450</u></b>

The accompanying Notes to the Consolidated Financial Statements on pages 6 to 11 form part of the consolidated interim financial statements.

## **1 Reporting Entity**

Green Cross Health Limited (the "Parent" or the "Company") is a New Zealand company registered under the Companies Act 1993 and is an FMC entity for the purposes of the Financial Reporting Act 2013 and the Financial Markets Conduct Act 2013. The Financial Statements have been prepared in accordance with these Acts. The Company is listed on the New Zealand Stock Exchange ("NZX").

The consolidated interim financial statements of Green Cross Health Limited comprise the Parent, its subsidiaries, and its interest in associates and joint ventures (together referred to as the "Group").

## **2 Basis of preparation of financial statements**

### **(a) Statement of compliance**

The consolidated interim financial statements have been prepared in accordance with Generally Accepted Accounting Practice ("NZ GAAP"), NZ IAS 34 Interim Financial Reporting, and other applicable Financial Reporting Standards as appropriate for profit oriented entities. These consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group as at and for the year ended 31 March 2024.

The consolidated interim financial statements for the six months ended 30 September 2024 and the comparative information for the six months ended 30 September 2023 are unaudited.

The interim financial statements were approved by the Board of Directors on 27 November 2024.

### **(b) Basis of measurement**

The interim financial statements of the Group are prepared under the historical cost basis unless otherwise noted within the specific accounting policies below.

### **(c) Changes in accounting policy**

The accounting policies applied by the Group in these consolidated interim financial statements are the same as those applied by the Group in its consolidated financial statements for the year ended 31 March 2024.

### **(d) Significant estimates and judgments**

In authorising the consolidated interim financial statements for the six months ended 30 September 2024, the Directors have ensured that the specific accounting policies necessary for the proper understanding of the interim financial statements have been disclosed, and that all accounting policies adopted are appropriate for the Group's circumstances and have been consistently applied throughout the period for all Group entities for the purposes of preparing the consolidated interim financial statements.

Inherent in the application of certain accounting policies, judgments and estimates are required. The Directors note that the actual results may differ from the judgments and estimates made.

The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

### 3 Segment reporting

The Group has two reportable segments: pharmacy services and medical services. The pharmacy services segment provides retail and dispensary services and the medical services segment provides GP, nursing and urgent care services.

The Group's main operations are in the pharmacy industry providing pharmacy services through consolidated stores, equity accounted investments and franchise stores. The medical services segment includes fully owned and equity accounted medical centres, and support services provided to these medical centres, as well as medical centres outside the Group.

#### Operating segments

	Note	Pharmacy services \$'000	Medical services \$'000	Corporate \$'000	Total \$'000
<b>30 September 2024 (Unaudited)</b>					
External revenues	4.1	182,215	77,659	-	259,874
Other income		3	-	-	3
Cost of products sold		(110,267)	(116)	-	(110,383)
Employee benefit expense		(40,884)	(57,075)	-	(97,959)
Lease expenses		(1,618)	(108)	-	(1,726)
Other expenses		(14,881)	(9,012)	(1,018)	(24,911)
Depreciation and amortisation		(1,552)	(946)	-	(2,498)
Depreciation - leases		(4,208)	(2,891)	-	(7,099)
Share of equity accounted net earnings		110	692	-	802
<b>Segment Profit</b>		<b>8,918</b>	<b>8,203</b>	<b>(1,018)</b>	<b>16,103</b>
Interest income					290
Interest expense					(1,170)
Interest expense - leases					(4,113)
<b>Profit before tax</b>					<b>11,110</b>
Tax expense					(3,021)
<b>Profit after tax</b>					<b>8,089</b>
Non-controlling interest					(2,442)
<b>Net Profit attributable to the shareholders of the Parent</b>					<b>5,647</b>
Reportable segment assets		278,611	124,451	(10,759)	392,303
Reportable segment liabilities		139,493	94,244	(10,759)*	222,978

\*Intersegmental elimination



### 3 Segment reporting (continued)

	Note	Pharmacy services \$'000	Medical services \$'000	Corporate \$'000	Total \$'000
<b>30 September 2023 (Unaudited)</b>					
External revenues	4.1	181,469	68,627	-	250,096
Other income		69	14	-	83
Cost of products sold		(106,030)	(149)	-	(106,179)
Employee benefit expense		(40,577)	(49,183)	-	(89,760)
Lease expenses		(2,511)	(194)	-	(2,705)
Other expenses		(18,047)	(8,530)	(1,049)	(27,626)
Depreciation and amortisation		(1,756)	(948)	-	(2,704)
Depreciation - leases		(4,314)	(2,686)	-	(7,000)
Share of equity accounted net earnings		349	379	-	728
<b>Segment Profit</b>		<u>8,652</u>	<u>7,330</u>	<u>(1,049)</u>	<u>14,933</u>
Interest income					357
Interest expense					(1,176)
Interest expense - leases					(3,597)
<b>Profit before tax</b>					<u>10,517</u>
Tax expense					(2,848)
<b>Profit after tax</b>					<u>7,669</u>
Non-controlling interest					(2,062)
<b>Net Profit attributable to the shareholders of the Parent</b>					<u>5,607</u>
Reportable segment assets		259,641	126,375	(11,078)	374,938
Reportable segment liabilities		132,361	91,018	(11,078)*	212,301

\*Intersegmental elimination

## 4 Operating performance

### 4.1 Revenue

The Group's operations and revenue streams are those described in the last annual financial statements. The Group's revenue is derived from contracts with customers.

<b>Revenue from contracts with customers</b>	<b>Six months ended 30 Sep 2024 (Unaudited) \$'000</b>	<b>Six months ended 30 Sep 2023 (Unaudited) \$'000</b>
Pharmacy retail and dispensary	164,945	160,743
Other pharmacy services	17,270	20,726
Medical services	<u>77,659</u>	<u>68,627</u>
	<b><u>259,874</u></b>	<b><u>250,096</u></b>

### Disaggregation of contract revenue

	<b>Reportable segments</b>		
	<b>Pharmacy services \$'000</b>	<b>Medical services \$'000</b>	<b>Total \$'000</b>
<b>Six months ended 30 September 2024 (Unaudited)</b>			
<b>Timing of revenue recognition</b>			
Transferred at a point in time	176,537	35,648	212,185
Transferred over time	<u>5,678</u>	<u>42,011</u>	<u>47,689</u>
	<b><u>182,215</u></b>	<b><u>77,659</u></b>	<b><u>259,874</u></b>

### Six months ended 30 September 2023 (Unaudited)

	<b>Pharmacy services \$'000</b>	<b>Medical services \$'000</b>	<b>Total \$'000</b>
<b>Timing of revenue recognition</b>			
Transferred at a point in time	175,890	30,684	206,574
Transferred over time	<u>5,579</u>	<u>37,943</u>	<u>43,522</u>
	<b><u>181,469</u></b>	<b><u>68,627</u></b>	<b><u>250,096</u></b>

### 4.2 Operating expenditure

	<b>Six months ended 30 Sep 2024 (Unaudited) \$'000</b>	<b>Six months ended 30 Sep 2023 (Unaudited) \$'000</b>
Cost of products sold	110,383	106,179
Employee benefit expense	97,959	89,760
Lease expenses	1,726	2,705
Other expenses	<u>24,911</u>	<u>27,626</u>
	<b><u>234,979</u></b>	<b><u>226,270</u></b>

## 5 Operating cash flow reconciliation

	Six months ended 30 Sep 2024 (Unaudited) \$'000	Six months ended 30 Sep 2023* (Unaudited) \$'000
Profit for the period	8,089	7,669
<b>Add/(deduct) non-cash items:</b>		
Depreciation, amortisation and impairment	9,597	9,704
Other non-cash items	(594)	(541)
<b>Add/(deduct) changes in working capital:</b>		
Receivable and accruals movement	1,180	(1,397)
Inventory	(2,630)	(816)
Payable and accruals movement	7,955	2,306
Provision for tax movement	(3,613)	(3,017)
<b>Add items classified as cash flows from financing activities:</b>		
Interest expense	1,170	819
Interest expense - leases	4,113	3,597
<b>Net cash inflow from operating activities</b>	<b>25,267</b>	<b>18,324</b>

\*Comparative information includes re-presentations for consistency with the current period.

## 6 Shares on issue

	As at 30 Sep 2024 (Unaudited) '000	As at 30 Sep 2023 (Unaudited) '000	As at 31 Mar 2024 (Audited) '000
<b>Shares authorised and on issue</b>			
Opening number of shares	143,462	143,285	143,285
Shares issued - fully paid	141	177	177
Shares issued - partly paid	-	-	-
Shares cancelled - partly paid	-	-	-
	<u>143,603</u>	<u>143,462</u>	<u>143,462</u>
Performance share rights	226	489	367
	<b>143,829</b>	<b>143,951</b>	<b>143,829</b>
Net tangible assets/(liabilities) per share (cents) <sup>^</sup>	(6.14)	(6.38)	(7.88)
Net assets per share (cents)*	117.91	113.37	116.13

<sup>^</sup>The calculation of net tangible assets / (liabilities) per share is based on net assets less deferred tax and intangible assets and the closing number of ordinary shares at the end of the period.

\*The calculation of net assets per share is based on net assets and the closing number of ordinary shares at the end of the period.

Performance share rights of 225,602 are on issue as at 30 September 2024. These were issued to some senior executives on 27 June 2022 and 26 June 2023.

## 7 Dividends

On 21 June 2024 Green Cross Health Limited paid a final dividend for the March 2024 year of 2.0 cents per qualifying ordinary share to shareholders, which was fully imputed at 28%.

	<b>Six months ended 30 Sep 2024 cents per share</b>	<b>Six months ended 30 Sep 2023 cents per share</b>	<b>Year ended 31 Mar 2024 cents per share</b>
Dividends per share	<u>2.00</u>	<u>31.50</u>	<u>34.00</u>

## 8 Subsequent events

On 27 November 2024, Green Cross Health Limited declared an interim dividend of 2.5 cents per qualifying ordinary share amounting to \$3.6m, which will be fully imputed at 28%. The dividend record date is 5 December 2024 and payment will occur on 18 December 2024.

No adjustment is required to these consolidated interim financial statements in respect of this event.

# Green Cross Health Limited Company Directory

## Board

**K Ellis**  
Independent Chair

**J A Bagnall**  
Non-Executive Director

**J B Bolland**  
Non-Executive Director

**C M Brockliss**  
Non-Executive Director

**P M Merton**  
Non-Executive Director

**K A Orr**  
Independent Director

**C M Steele**  
Independent Director

## Officers

**Rachael Newfield**  
Group CEO

**Kalpana Goundar**  
CFO/Company Secretary

## Registered office

Green Cross Health Limited  
Ground Floor, Building B  
602 Great South Road  
Ellerslie, Auckland 1051  
Telephone: +64 9 571 9080

## Share register

Computershare Investor Services Limited  
Private Bag 92119  
Auckland 1142  
Level 2, 159 Hurstmere Road  
Takapuna, Auckland 0622

Managing your shareholding online:  
To change your address, update your payment instructions and to view your registered details including transactions, please visit:  
[www.investorcentre.com/nz](http://www.investorcentre.com/nz)

General enquiries can be directed to:  
[enquiry@computershare.co.nz](mailto:enquiry@computershare.co.nz)  
Telephone: +64 9 488 8700  
Facsimile: +64 9 488 8787

Please assist our registrar by quoting your CSN or shareholder number.

## Auditor

KPMG  
KPMG Centre  
18 Viaduct Harbour Avenue  
Auckland Central  
Auckland 1010

## **Green Cross Health Limited Company Directory (continued)**

### **Bankers**

Bank of New Zealand  
80 Queen Street  
Auckland Central  
Auckland 1010

Bank of China  
205 Queen Street  
Auckland Central  
Auckland 1010

### **Investor relations**

For investor relations enquiries:  
Phone: 09 571 9088  
Email: [investorrelations@gxh.co.nz](mailto:investorrelations@gxh.co.nz)

### **Websites**

[www.greencrosshealth.co.nz](http://www.greencrosshealth.co.nz)  
[www.thedoctorsonline.co.nz](http://www.thedoctorsonline.co.nz)  
[www.lifepharmacy.co.nz](http://www.lifepharmacy.co.nz)  
[www.livingrewards.co.nz](http://www.livingrewards.co.nz)  
[www.pilldrop.co.nz](http://www.pilldrop.co.nz)  
[www.thedoctors.co.nz](http://www.thedoctors.co.nz)  
[www.unichem.co.nz](http://www.unichem.co.nz)